SHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so.

See related article by Feng et al., p. 5297

©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.